|
''BioDrugs'' is a peer-reviewed pharmacology journal. It has an impact factor of 2.989.〔(【引用サイトリンク】title=BioDrugs - home )〕 It is published by Adis International (Springer Science + Business Media) ''BioDrugs'' aims to advance discussion and evaluation of the latest developments in the clinical application of biotechnology for the treatment of human disease by providing a programme of review articles and original research covering the most important aspects of biotechnology-based pharmaceuticals, diagnostic products and innovations in bio-tech therapy. This includes novel drug delivery systems; protein/peptide therapeutics; monoclonal antibodies, antibody fragments and antibody engineering; biosimilars; cytokines and cytokine receptors; recombinant DNA and gene regulation technology; gene therapy; nucleic acid therapeutics and diagnostics; stem cell therapies; drug target validation; glycolated and pegylated therapeutics; and pioneering technologies in drug design and development. ''BioDrugs'' publishes articles on all areas of medicine. Abstracted/Indexed in:- PubMed/Medline, SCOPUS, EMBASE, Google Scholar, EBSCO, CSA, CAB International, Academic OneFile, Academic Search, ASFA, CAB Abstracts, Current Abstracts, Expanded Academic, Global Health, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「BioDrugs」の詳細全文を読む スポンサード リンク
|